多基原中药质量评价是保障其临床用药有效性和安全性的重要环节。目前，多基原中药质量评价仍存在基原鉴定方法专属性较差，多基原中药品种间药效和毒性物质基础不明确，有效性、安全性数据缺乏等问题。近年来，围绕多基原中药质量评价涌现出许多新思路、新模式及新方法。在整理《中国药典》2020年版收载的多基原中药概况的基础上，对多基原中药基原鉴定及质量评价新思路、新方法进行综述。为完善多基原中药质量评价体系，保障多基原中药临床用药的有效性和安全性提供支持。

The quality evaluation of multi-source traditional Chinese medicine (TCM) is an important step to ensure its clinical efficacy and safety. At present, there are still some problems in the quality evaluation of multi-source TCM, such as poor specificity of the identification methods, unclear material basis of efficacy and toxic among the varieties of multi-source TCM, and lack of efficacy and safety data. In recent years, novel ideas, models and methods have emerged around the quality evaluation of multi-source TCM. Based on the profile of multi-source TCM collected in Chinese Pharmacopoeia 2020 edition, this paper expounds the novel ideas and methods of the identification and quality evaluation of multi-source TCM, it is expected to provide support to improve the quality evaluation system of multi-source TCM and ensure the efficacy and safety in clinical use.

R282

国家自然科学基金资助项目（82004225）